Spotify vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
NASDAQ: SPOT | 640M+ monthly active users; 276M paid subscribers; $16.3B revenue FY2024; first profitable year; 100M+ audiobook listeners; AI DJ and podcast originals driving retention
About
Spotify is the world's largest audio streaming platform, founded in 2006 in Stockholm, Sweden, by Daniel Ek and Martin Lorentzon with the mission of giving artists a platform to reach new audiences and listeners access to all the world's music. The platform's core technology combines a massive music catalog with a recommendation engine — Discover Weekly, Daily Mixes, and the AI DJ launched in 2023 — that has made personalized audio discovery its defining competitive advantage.\n\nSpotify's product portfolio spans music, podcasts, and audiobooks delivered through a freemium model: a free ad-supported tier and a premium subscription tier. The platform hosts over 100 million tracks, 6 million podcasts, and 350,000 audiobooks. Its AI DJ and podcast creation tools have expanded creator capabilities, while the Spotify Wrapped annual feature drives massive organic engagement. With 696 million monthly active users and 276 million paying subscribers, Spotify serves listeners across 180+ markets.\n\nSpotify recorded its first full-year profit in 2024, a landmark milestone following years of investment-heavy growth, and reached $15B+ in annual revenue. The company commands a dominant share of global music streaming and has used its scale to push into adjacent audio formats — podcasts and audiobooks — to diversify revenue and deepen daily listening habits. Its combination of unmatched catalog depth, best-in-class personalization, and a growing creator ecosystem entrenches it as the default audio platform for a generation of listeners.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.